Key facts
- This page summarizes Nancy E. Denyes's Form 4 filing for aTYR PHARMA INC (ATYR).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 09 Jan 2026, 17:40.
Nancy E. Denyes - 09 Jan 2026 Form 4 Insider Report for aTYR PHARMA INC (ATYR)
- Reporting relationship
- General Counsel
- Issuer ticker
- ATYR
- Reported as of
- 09 Jan 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Jan 2026, 17:40:29 UTC
- Prior SEC filing
- 04 Feb 2025
- Next SEC filing
- 04 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nancy E. Denyes
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Nancy E. Denyes filed Form 4 for aTYR PHARMA INC (ATYR) on 09 Jan 2026.
Change
- Previous filing in this sequence was filed on 04 Feb 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001640869
Primary reporting owner
DENYES NANCY
- Relationship
- General Counsel
- Address
- 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO
- Signature
- /s/ Nancy E. Denyes
- Signature date
- 09 Jan 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATYR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 31,555
- Date
- 09 Jan 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ATYR
transaction
Derivative
Employee Stock Options (right to buy)
Award
- Transaction value
- $0
- Shares
- +412,500
- Change %
- Price
- $0.000000
- Shares after
- 412,500
- Date
- 09 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 412,500
- Exercise price
- $0.7127
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Includes 2,500 shares acquired on May 15, 2025 and 2,500 shares acquired on November 14, 2025 under the Company's 2015 Employee Purchase Plan.
Footnote F2
The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning February 9, 2026, such that this option will be fully exercisable on January 9, 2029. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.